MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot Study
Evidence accumulated so far indicates that circulating levels of microRNAs (miRNAs) are associated with several pathologies. Therefore, differential expression of extracellular miRNAs exhibits promising potential for screening and diagnosis purposes. We evaluated plasma miRNAs in response to the lip...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.674252/full |
| _version_ | 1819135682219606016 |
|---|---|
| author | Carmen Gloria Ubilla Yalena Prado Jeremy Angulo Ignacio Obreque Isis Paez Nicolás Saavedra Kathleen Saavedra Tomás Zambrano Luis A. Salazar |
| author_facet | Carmen Gloria Ubilla Yalena Prado Jeremy Angulo Ignacio Obreque Isis Paez Nicolás Saavedra Kathleen Saavedra Tomás Zambrano Luis A. Salazar |
| author_sort | Carmen Gloria Ubilla |
| collection | DOAJ |
| description | Evidence accumulated so far indicates that circulating levels of microRNAs (miRNAs) are associated with several pathologies. Therefore, differential expression of extracellular miRNAs exhibits promising potential for screening and diagnosis purposes. We evaluated plasma miRNAs in response to the lipid-lowering drug atorvastatin in patients with hypercholesterolemia (HC) and controls. Methods: We selected miRNAs based on previous data reported by our group and also by employing bioinformatics tools to identify 10 miRNAs related to cholesterol metabolism and statin response genes. Following miRNA identification, we determined plasma levels of miRNA-17-5p, miRNA-30c-5p, miRNA-24-3p, miRNA-33a-5p, miRNA-33b-5p, miRNA-29a-3p, miRNA-29b-3p, miRNA-454-3p, miRNA-590-3p and miRNA-27a-3p in 20 HC patients before and after 1 month of 20 mg/day atorvastatin treatment, evaluating the same miRNA set in a group of 20 healthy subjects, and employing qRT-PCR to determine differential miRNAs expression. Results: HC individuals showed significant overexpression of miRNA-30c-5p and miRNA-29b-3p vs. NL (p = 0.0008 and p = 0.0001, respectively). Once cholesterol-lowering treatment was concluded, HC individuals showed a substantial increase of three extracellular miRNAs (miRNA-24-3p, miRNA-590, and miRNA-33b-5p), the latter elevated more than 37-fold (p = 0.0082). Conclusion: Data suggest that circulating miRNA-30c-5p and miRNA-29b-3p are associated with hypercholesterolemia. Also, atorvastatin induces a strong elevation of miRNA-33b-5p levels in HC individuals, which could indicate an important function that this miRNA may exert upon atorvastatin therapy. Additional studies are needed to clarify the role of this particular miRNA in statin treatment. |
| first_indexed | 2024-12-22T10:22:58Z |
| format | Article |
| id | doaj.art-c9f8c3b5acd54efcbb87e454a28a165b |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-22T10:22:58Z |
| publishDate | 2021-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-c9f8c3b5acd54efcbb87e454a28a165b2022-12-21T18:29:35ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-05-011210.3389/fphar.2021.674252674252MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot StudyCarmen Gloria Ubilla0Yalena Prado1Jeremy Angulo2Ignacio Obreque3Isis Paez4Nicolás Saavedra5Kathleen Saavedra6Tomás Zambrano7Luis A. Salazar8Center of Molecular Biology and Pharmacogenetics, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, ChileCenter of Molecular Biology and Pharmacogenetics, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, ChileCenter of Molecular Biology and Pharmacogenetics, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, ChileCenter of Molecular Biology and Pharmacogenetics, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, ChileCenter of Molecular Biology and Pharmacogenetics, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, ChileCenter of Molecular Biology and Pharmacogenetics, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, ChileCenter of Molecular Biology and Pharmacogenetics, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, ChileDepartment of Medical Technology, Faculty of Medicine, Universidad de Chile, Santiago, ChileCenter of Molecular Biology and Pharmacogenetics, Department of Basic Sciences, Faculty of Medicine, Universidad de La Frontera, Temuco, ChileEvidence accumulated so far indicates that circulating levels of microRNAs (miRNAs) are associated with several pathologies. Therefore, differential expression of extracellular miRNAs exhibits promising potential for screening and diagnosis purposes. We evaluated plasma miRNAs in response to the lipid-lowering drug atorvastatin in patients with hypercholesterolemia (HC) and controls. Methods: We selected miRNAs based on previous data reported by our group and also by employing bioinformatics tools to identify 10 miRNAs related to cholesterol metabolism and statin response genes. Following miRNA identification, we determined plasma levels of miRNA-17-5p, miRNA-30c-5p, miRNA-24-3p, miRNA-33a-5p, miRNA-33b-5p, miRNA-29a-3p, miRNA-29b-3p, miRNA-454-3p, miRNA-590-3p and miRNA-27a-3p in 20 HC patients before and after 1 month of 20 mg/day atorvastatin treatment, evaluating the same miRNA set in a group of 20 healthy subjects, and employing qRT-PCR to determine differential miRNAs expression. Results: HC individuals showed significant overexpression of miRNA-30c-5p and miRNA-29b-3p vs. NL (p = 0.0008 and p = 0.0001, respectively). Once cholesterol-lowering treatment was concluded, HC individuals showed a substantial increase of three extracellular miRNAs (miRNA-24-3p, miRNA-590, and miRNA-33b-5p), the latter elevated more than 37-fold (p = 0.0082). Conclusion: Data suggest that circulating miRNA-30c-5p and miRNA-29b-3p are associated with hypercholesterolemia. Also, atorvastatin induces a strong elevation of miRNA-33b-5p levels in HC individuals, which could indicate an important function that this miRNA may exert upon atorvastatin therapy. Additional studies are needed to clarify the role of this particular miRNA in statin treatment.https://www.frontiersin.org/articles/10.3389/fphar.2021.674252/fullhypercholesterolemiacirculating microRNAsatorvastatinepidrugsstatins |
| spellingShingle | Carmen Gloria Ubilla Yalena Prado Jeremy Angulo Ignacio Obreque Isis Paez Nicolás Saavedra Kathleen Saavedra Tomás Zambrano Luis A. Salazar MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot Study Frontiers in Pharmacology hypercholesterolemia circulating microRNAs atorvastatin epidrugs statins |
| title | MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot Study |
| title_full | MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot Study |
| title_fullStr | MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot Study |
| title_full_unstemmed | MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot Study |
| title_short | MicroRNA-33b is a Potential Non-Invasive Biomarker for Response to Atorvastatin Treatment in Chilean Subjects With Hypercholesterolemia: A Pilot Study |
| title_sort | microrna 33b is a potential non invasive biomarker for response to atorvastatin treatment in chilean subjects with hypercholesterolemia a pilot study |
| topic | hypercholesterolemia circulating microRNAs atorvastatin epidrugs statins |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.674252/full |
| work_keys_str_mv | AT carmengloriaubilla microrna33bisapotentialnoninvasivebiomarkerforresponsetoatorvastatintreatmentinchileansubjectswithhypercholesterolemiaapilotstudy AT yalenaprado microrna33bisapotentialnoninvasivebiomarkerforresponsetoatorvastatintreatmentinchileansubjectswithhypercholesterolemiaapilotstudy AT jeremyangulo microrna33bisapotentialnoninvasivebiomarkerforresponsetoatorvastatintreatmentinchileansubjectswithhypercholesterolemiaapilotstudy AT ignacioobreque microrna33bisapotentialnoninvasivebiomarkerforresponsetoatorvastatintreatmentinchileansubjectswithhypercholesterolemiaapilotstudy AT isispaez microrna33bisapotentialnoninvasivebiomarkerforresponsetoatorvastatintreatmentinchileansubjectswithhypercholesterolemiaapilotstudy AT nicolassaavedra microrna33bisapotentialnoninvasivebiomarkerforresponsetoatorvastatintreatmentinchileansubjectswithhypercholesterolemiaapilotstudy AT kathleensaavedra microrna33bisapotentialnoninvasivebiomarkerforresponsetoatorvastatintreatmentinchileansubjectswithhypercholesterolemiaapilotstudy AT tomaszambrano microrna33bisapotentialnoninvasivebiomarkerforresponsetoatorvastatintreatmentinchileansubjectswithhypercholesterolemiaapilotstudy AT luisasalazar microrna33bisapotentialnoninvasivebiomarkerforresponsetoatorvastatintreatmentinchileansubjectswithhypercholesterolemiaapilotstudy |